Terapi Osteoporosis Terbaru: Tinjauan Komprehensif Farmakologis

Raymond R. Tjandrawinata

doi:10.56951/d4enjy05

Terapi Osteoporosis Terbaru: Tinjauan Komprehensif Farmakologis

Penulis

Raymond R. Tjandrawinata Molecular Pharmacologist, Dexa Group

DOI:

https://doi.org/10.56951/d4enjy05

Kata Kunci:

osteoporosis, terapi farmakologis, bisphosphonate, denosumab, terapi anabolik

Abstrak

Osteoporosis adalah penyakit metabolik tulang yang ditandai dengan penurunan massa dan gangguan mikroarsitektur tulang sehingga meningkatkan risiko fraktur. Pendekatan farmakologis terbaru mencakup agen antiresorptif seperti bisphosphonates dan denosumab, serta terapi anabolik seperti teriparatide dan romosozumab yang berperan dalam
meningkatkan kepadatan mineral tulang. Selain pengobatan, suplementasi kalsium dan vitamin D serta modifikasi gaya hidup berperan dalam pencegahan dan pengelolaan osteoporosis. Pemantauan berkala terhadap kepadatan tulang dan efektivitas terapi diperlukan untuk menyesuaikan strategi pengobatan secara personalisasi dan meminimalkan efek samping. Dengan integrasi terapi berbasis biomarker, pendekatan multidisiplin dalam pengelolaan osteoporosis dapat semakin ditingkatkan untuk meningkatkan kualitas hidup pasien.

Unduhan

Baca Selengkapnya

Referensi

1. Cheng C, Wentworth K, Shoback D. New frontiers in osteoporosis therapy. Ann Rev Med. 2020;71:277-88.

doi:10.1146/annurev-med-052218-020620.

2. Ompusunggu IHR, Immanuel. A comprehensive literature review of osteoporosis treatment and fracture outcomes. Indones J Gen Med. 2024;7(4):16-29. doi:10.70070/rs5yc355.

3. He J, Zeng W, Ye X, Niu X, Liu J, Chen Z. Targeted drug delivery for precision mitochondrial therapy in osteoporosis: therapeutic strategies and advances. Curr Drug Ther. 2024;19(2):125-40. doi:10.2174/0115748855342971240816120237.

4. Kuril A, Manchuri KM, Anand SP. Emerging protein and peptide therapeutics for osteoporosis: advances in anabolic and catabolic treatments. J Pharm Res Int. 2024;36(11):7603-15. doi:10.9734/jpri/2024/v36i117603.

5. Reid I. Efficacy, effectiveness, and side effects of medications used to prevent fractures. J Intern Med.2015;277(6):690-706. doi:10.1111/joim.12339.

6. Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus M. Secondary contributors to bone loss in osteoporosis-related hip fractures. Osteoporos Int. 2008;19(7):991-9. doi:10.1007/s00198-007-0525-7.

7. Carey DE, Golden NH. Bone health in adolescence. Pediatrics. 2015;136(4):e123-38. doi:10.1542/peds.2015-2310.

8. Syam Y, Noersasongko D, Sunaryo H. Fraktur akibat osteoporosis. J e-CliniC. 2014;2(2):4885. doi:10.35790/ecl.2.2.2014.4885.

9. Saag K. Osteoporosis for rheumatologists: latest updates and controversies. J Clin Rheumatol Immunol. 2024;18(1):112-25. doi:10.1142/s2661341724740122.

10. Tariq F, Ahmad M, Subhan M, Alvi SMZ, Tariq MU, Ullah S, et al. The management of osteoporosis in chronic kidney disease: a review of diagnostic and therapeutic approaches. Cureus. 2024;16(3):e73882.

doi:10.7759/cureus.73882.

11. Thompson JC, Wanderman N, Anderson P, Freedman B. Abaloparatide and the spine: a narrative review. Clin Interv Aging. 2020;15:2335-46. doi:10.2147/CIA.S227611.

12. Li N, Cornelissen D, Pinto D, Silverman S, Si L, Kremer I, et al. An updated systematic review of costeffectiveness analyses of drugs for osteoporosis. Osteoporos Int. 2019;30(2):567-80. doi:10.1007/

s00198-018-4742-3.

13. Haas AV, LeBoff MS. Osteoanabolic agents for osteoporosis. J Endocr Soc. 2018;2(8):934-47. doi:10.1210/js.2018-00118.

1. Cheng C, Wentworth K, Shoback D. New frontiers in osteoporosis therapy. Ann Rev Med. 2020;71:277-88. doi:10.1146/annurev-med-052218-020620.

2. Ompusunggu IHR, Immanuel. A comprehensive literature review of osteoporosis treatment and fracture outcomes. Indones J Gen Med. 2024;7(4):16-29. doi:10.70070/rs5yc355.

3. He J, Zeng W, Ye X, Niu X, Liu J, Chen Z. Targeted drug delivery for precision mitochondrial therapy in osteoporosis: therapeutic strategies and advances. Curr Drug Ther. 2024;19(2):125-40. doi:10.2174/0115748855342971240816120237.

4. Kuril A, Manchuri KM, Anand SP. Emerging protein and peptide therapeutics for osteoporosis: advances in anabolic and catabolic treatments. J Pharm Res Int. 2024;36(11):7603-15. doi:10.9734/jpri/2024/v36i117603.

5. Reid I. Efficacy, effectiveness, and side effects of medications used to prevent fractures. J Intern Med. 2015;277(6):690-706. doi:10.1111/joim.12339.

6. Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus M. Secondary contributors to bone loss in osteoporosis-related hip fractures. Osteoporos Int. 2008;19(7):991-9. doi:10.1007/s00198-007-0525-7.

7. Carey DE, Golden NH. Bone health in adolescence. Pediatrics. 2015;136(4):e123-38. doi:10.1542/peds.2015-2310.

8. Syam Y, Noersasongko D, Sunaryo H. Fraktur akibat osteoporosis. J e-CliniC. 2014;2(2):4885.doi:10.35790/ecl.2.2.2014.4885.

9. Saag K. Osteoporosis for rheumatologists: latest updates and controversies. J Clin Rheumatol Immunol. 2024;18(1):112-25. doi:10.1142/s2661341724740122.

10. Tariq F, Ahmad M, Subhan M, Alvi SMZ, Tariq MU, Ullah S, et al. The management of osteoporosis in chronic kidney disease: a review of diagnostic and therapeutic approaches. Cureus. 2024;16(3):e73882. doi:10.7759/cureus.73882.

11. Thompson JC, Wanderman N, Anderson P, Freedman B. Abaloparatide and the spine: a narrative review. Clin Interv Aging. 2020;15:2335-46. doi:10.2147/CIA.S227611.

12. Li N, Cornelissen D, Pinto D, Silverman S, Si L, Kremer I, et al. An updated systematic review of costeffectiveness analyses of drugs for osteoporosis. Osteoporos Int. 2019;30(2):567-80. doi:10.1007/s00198-018-4742-3.

13. Haas AV, LeBoff MS. Osteoanabolic agents for osteoporosis. J Endocr Soc. 2018;2(8):934-47. doi:10.1210/js.2018-00118.

31. Ramayulis R, Pramantara IDP, Pangastuti R. Asupan vitamin, mineral, rasio asupan kalsium dan fosfor dan hubungannya dengan kepadatan mineral tulang kalkaneus wanita. Indones J Clin Nutr. 2011;8(1):52-60. doi:10.22146/ijcn.17752.

32. Kristiningrum E, Anggraeni P, Widyastuti A, Hapsari BW. Perancangan kerangka kerja standar pangan fungsional untuk membantu penyerapan kalsium. J Standarisasi. 2019;21(1):1-10. doi:10.31153/js.v21i1.733.

33. Irfan U, Irfan A, Malik AL, Iqbal M, Mehboob I. Vitamin D insufficiency in four major hospitals of Punjab. Pak Postgrad Med J. 2018;29(4):142-4. doi:10.51642/ppmj.v29i4.39.

34. Singh W, Kushwaha P. Potassium: a frontier in osteoporosis. Horm Metab Res. 2023;55(3):189-97.

doi:10.1055/a-2254-8533.

35. Barrionuevo P, Gionfriddo MR, Castaneda-Guarderas A, Zeballos-Palacios C, Bora PR, Mohammed K,

et al. Women’s values and preferences regarding osteoporosis treatments: a systematic review. J Clin

Endocrinol Metab. 2019;104(5):1631-6. doi:10.1210/jc.2019-00193.

36. Wang J, Xue M, Hu Y, Li J, Li Z, Wang Y. Proteomic insights into osteoporosis: unraveling diagnostic markers

and therapeutic targets for the metabolic bone disease. Biomolecules. 2024;14(5):554. doi:10.3390/

biom14050554.

37. Xue W, Awang Z. Application of nutritional, pharmacological, and physical therapy interventions in delaying

degenerative changes: systematic review. J Ecohumanism. 2025;3(8):5708. doi:10.62754/joe.v3i8.5708.

38. Novarinda Z, Nuryanto N. Hubungan lingkar pinggang, asupan zat gizi, dan aktivitas fisik dengan kepadatan

tulang pada wanita usia 30–50 tahun. J Nutr Pangan. 2015;10(1):62-8. doi:10.14710/jnc.v4i1.8625.

39. Zhong Y, Li J, Luo J, Chen F. Advances in bone turnover markers (PINP and CTX) in optimizing antiresorptive and anabolic therapies against osteoporosis. Discov Med. 2024;28(154):89-98. doi:10.3410/f.726489290.793536687.

40. Calvi LM, Bush EC. Improved in vivo experimental screening identifies an anabolic analog of 1,25 dihydroxyvitamin D3 with minimal bone resorption activity. J Bone Miner Res. 2020;35(12):2332-45. doi:10.1002/jbmr.3933.

41. Lin L, Xu P, Mo Y, Tan R, Li D. RNA-binding proteins: biological mechanisms and their impact on osteoporosis

development. Light Sci Appl. 2024;13(1):88. doi:10.1038/s41377-024-00988-8.

42. Chen Y, Xiao H, Liu Z, Teng F, Yang A, Geng B, et al. Sirt1: an increasingly interesting molecule with a potential role in bone metabolism and osteoporosis. Biomolecules. 2024;14(8):970. doi:10.3390/biom14080970.

43. Cheung KCP, Ma J, Chen X, Jia W. Extracellular vesicles derived from host and gut microbiota as promising nanocarriers for targeted therapy in osteoporosis and osteoarthritis. Front Pharmacol. 2023;13:Article 1051134. doi:10.3389/fphar.2022.1051134.